Compare CEVA & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CEVA | PAHC |
|---|---|---|
| Founded | 1999 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2002 | 2014 |
| Metric | CEVA | PAHC |
|---|---|---|
| Price | $36.22 | $34.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | $30.33 | ★ $41.25 |
| AVG Volume (30 Days) | ★ 636.9K | 270.7K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | N/A | ★ 1883.33 |
| EPS | N/A | ★ 1.90 |
| Revenue | $87,507,000.00 | ★ $833,350,000.00 |
| Revenue This Year | $12.37 | $17.03 |
| Revenue Next Year | $13.82 | $3.82 |
| P/E Ratio | ★ N/A | $17.92 |
| Revenue Growth | ★ 20.45 | 4.12 |
| 52 Week Low | $17.02 | $25.58 |
| 52 Week High | $51.60 | $60.08 |
| Indicator | CEVA | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 54.07 |
| Support Level | $35.61 | $30.55 |
| Resistance Level | $49.89 | $34.67 |
| Average True Range (ATR) | 2.64 | 1.25 |
| MACD | -0.77 | 0.28 |
| Stochastic Oscillator | 3.46 | 79.28 |
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived mainly from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems. The company operates in one reportable segment: the licensing of IP to semiconductor companies and electronic equipment manufacturers.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.